Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
By M. Law, N. J. Wald, J. Morris, Rachel E Jordan. British medical journal, 2003
1,241 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/7424d3aa21e6e5328cb26263bc8da99781b7f0fb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. (2007, background): “Nonetheless, available evidence has shown that the incidence of adverse drug reactions is relatively low, generally occurs during the early rather than late phases of therapy, and is unlikely to entirely account for nonadherence, especially to statins or other preventive therapies.(32,33)”
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. (2007, neutral): “Although this approach might not produce the largest blood pressure reductions possible, it will shift the entire distribution of blood pressure values down in patients with diabetes, with minimum requirements for titration and, potentially, with fewer side-effects.(12)”
- Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure (2005, methodology): “recommend adding 10 mm Hg to treated SBP measurements [23, 42], although adding 15 mm Hg may also be advocated [43].”
- Drugs, their targets and the nature and number of drug targets (2006, background): “However, there is an increasing readiness to challenge this paradig”
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “An increase in the dose of antihypertensive drugs other than ACE inhibitors and ARBs increases the frequency of adverse effects [687].”
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies (2009, background): “As the reduction in blood pressure was not reported in most trials of people with a history of CHD, we estimated the average reduction from the average blood pressure before treatment and the average drug dose (as a multiple of standard dose”